United States FDA gets serious about biosimilars
5 September 2018
The most significant advances in medical treatments are being made with biological products.
Read on
biosimilars
Is the cure in your DNA? – The rise of biopharmaceuticals and pharmacogenomics-led therapy
4 June 2018
15 years has passed since the Human Genome Project, involving the identification and mapping of all the genes of the human genome, was declared complete.
Read on
The Budget 2018-2019: our three key areas for intellectual property
9 May 2018
Biotechnology companies and generic pharmaceuticals are the winners and celebrities are the Biggest Losers in the Federal Budget
Read on
Biosimilars: balancing access to affordable medicines with safety
3 November 2017
Biological medicines (biologics) are agents derived from a biological source.
Read on
Don’t you wanna dance with me? US Supreme Court to hear Amgen v Sandoz biosimilars case
24 January 2017
The US Supreme Court has granted petitions for certiorari in Amgen v.
Read on
The Trans-Pacific Partnership’s IP provisions: Biologics and biosimilars, copyright and privacy
9 October 2015
The Trans-Pacific Partnership (TPP) was concluded on 5 October 2015, after 8 years of negotiations.
Read on